Multiplex Real-time PCR Detection of Intestinal Protozoa in HIV-infected Children in Malawi: Enterocytozoon Bieneusi Is Common and Associated With Gastrointestinal Complaints and May Delay BMI (Nutritional Status) Recovery by Huibers, M.H.W. et al.
910 | www.pidj.com The Pediatric Infectious Disease Journal • Volume 37, Number 9, September 2018
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. 
This is an open-access article distributed under the terms of the Creative 
Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it 
is permissible to download, share, remix, transform, and buildup the work 
provided it is properly cited. The work cannot be used commercially without 
permission from the journal.
HIV Reports
Background: Intestinal protozoa are common opportunistic infections in 
HIV patients. Longitudinal studies on either the clinical relevance or the 
effect of immune reconstitution by antiretroviral therapy on intestinal pro-
tozoan infections in children are lacking however. This study investigates 
prevalence and clinical relevance of intestinal protozoa in HIV-infected 
Malawian children before and during their first year of antiretroviral treat-
ment (ART).
Methods: Stool samples collected at enrolment and during follow-up were 
tested for nonopportunistic (Giardia lamblia, Dientamoeba fragilis, Enta-
moeba histolytica) and opportunistic protozoa (Enterocytozoon bieneusi, 
Encephalitozoon spp., Cryptosporidium spp. and Cystoisospora belli) using 
multiplex real-time polymerase chain reaction. Associations between infec-
tions and clinical symptoms were evaluated using univariate methods.
Results: Nonopportunistic and opportunistic protozoa were detected in 
40% (14/35) and 46% (16/35) of children at baseline, respectively. E. bie-
neusi was the most prevalent protozoa (37%, 13/35) and associated with 
gastrointestinal complaints (43% in positive (10/13) versus 18% (4/22) in E. 
bieneusi-negative children, P = 0.001. Body mass index recovery during 12 
months of ART was more commonly delayed in E. bieneusi-positive chil-
dren (+0.29 +standard deviation 0.83) than E. bieneusi-negative children 
(+1.03 +standard deviation 1.25; P = 0.05). E. bieneusi was not detected 
after 12 months of ART.
Conclusions: E. bieneusi was the most prevalent opportunistic intestinal 
protozoa, present in over a third of study participants before initiation of 
ART. Although all children cleared E. bieneusi after 12 months of ART, 
E. bieneusi was associated with gastrointestinal complaints and may delay 
body mass index recovery. Trials to assess effect of treatment of E. bieneusi 
on nutritional status should be considered in HIV-infected African children.
Key Words: intestinal protozoa, microsporidiosis, Giardia lamblia, Dienta-
moeba fragilis, Entamoeba histolytica, Enterocytozoon bieneusi, Encepha-
litozoon spp., cryptosporidium, HIV, antiretroviral treatment
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Intestinal protozoal infections, caused either by opportunistic or nonopportunistic species, can complicate HIV infection in adults 
and children. Protozoal infections can cause chronic diarrhea and 
thereby malabsorption leading to malnutrition and dehydration, 
contributing to the high rates of morbidity and mortality observed 
in resource-limited settings.1–3 Prevalence data on protozoal infec-
tions in patients with chronic diarrhea range widely between 1% 
and 75%, which can be explained by differences in demographics, 
seasonal variance and diagnostic methods.4,5 Prevalence rates are 
higher in those studies employing modern, more sensitive, poly-
merase chain reaction (PCR) techniques.6,7 However, PCR tech-
niques are not commonly available in resource-limited settings and 
therefore reliable data from these areas are scarce.
Treatment of HIV infection has greatly improved over the 
past decade because of the massive scale up of antiretroviral treat-
ment (ART) availability. In general, ART reduces HIV viral load, 
permits immune reconstitution and reduces the risk of new oppor-
tunistic infections.8 Reduction of the prevalence of intestinal pro-
tozoa in HIV-infected adults after introduction of ART has been 
documented both in industrialized nations and resource-limited 
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settings.9–11 However, prospective data on children receiving ART 
are lacking. Longitudinal data are needed to clarify which oppor-
tunistic infection may resolve through immune reconstitution 
because of ART alone and which infections might require more 
targeted therapy.
Therefore, this prospective cohort study was conducted to 
document the prevalence of opportunistic and nonopportunistic 
intestinal protozoa in HIV-infected children in Malawi, during the 
first year of first-line ART, using multiplex real-time PCR tech-
niques. Additionally, the study investigated the dynamics and clini-
cal aspects of the most common infections to evaluate their contri-
bution to clinical symptoms and morbidity in Malawian children.
MATERIALS AND METHODS
Study Population
The study cohort included ART-naïve HIV-infected children 
initiating ART at the Queen Elizabeth Central Hospital, Blantyre, 
Malawi. Children 18 months to 18 years of age were enrolled before 
initiating ART, if they met ART initiation criteria outlined in the 
Malawi National ART program guidelines (2010–2012).12,13 Local 
guidelines, applicable at the time of the study have been described 
in detail elsewhere.14 In short, ART was initiated in children based 
on World Health Organization (WHO) staging and immune status. 
Clinical criteria included: ≥18 months of age with WHO clinical 
stage 3 and severe immune suppression was based on the WHO 
guideline at the time of the study: for children <59 months of age 
by CD4% <25% and/or CD4 <750 cells/mm and children >59 
months of age CD4 <350 cells/mm.12
Data Collection
Following recruitment and informed consent, a standardized 
history was collected, including socioeconomic data and gastroin-
testinal symptoms. A physical examination was performed includ-
ing collection of anthropometry. Children were monitored via data 
collection evaluating symptoms and anthropometry throughout the 
first 12 months of ART. Blood and stool samples were collected 
at 0, 6 and 12 months. This intestinal protozoa study was nested 
within a larger ART follow-up cohort study. Stool samples were 
stored and determined at a later point in time. All physicians were 
unaware of the PCR results.
Laboratory
HIV infection was confirmed using 2 HIV antibody tests 
(Abbott Determine HIV-1/2 Test and Uni-Gold HIV test). Full 
blood count (Beckman Coulter HMX, Beckman coulter, CA) and 
CD4 count (flow cytometry, Becton Dickinson, CA) were ana-
lyzed at the MLW Clinical Research Programme laboratory. Ali-
quots were stored for batch analysis of HIV-1 viral load (Roche 
Amplicor; Roche, Basel, Switzerland). Stool samples were stored 
at −20°C within 24 hours after sampling and subsequently shipped 
to Leiden University Medical Center, Leiden, The Netherlands. 
DNA isolation, amplification and detection were performed at Lei-
den University Medical Center as described elsewhere with some 
modifications, in particular the combinations of targets.15–17 One 
multiplex real-time PCR was used for the detection of DNA of the 
nonopportunistic protozoa Giardia lamblia, Dientamoeba fragilis 
and Entamoeba histolytica15 and another multiplex real-time PCR 
targeted opportunistic protozoa including microsporidia Entero-
cytozoon bieneusi and Encephalitozoon spp. (ie, Encephalitozoon 
intestinalis)18 with Cryptosporidium spp.16 and Cystoisospora 
belli.17 Appropriate positive and negative controls were included in 
each assay. The PCR output consisted of a cycle threshold (Ct-) 
value representing the amplification cycle in which the level of 
fluorescent signal exceeded the background fluorescence. Intensity 
of infection was categorized for each target into low, moderate and 
high DNA levels based on Ct value, respectively: higher than 35, 
between 35 and 30 and lower than 30, while negative PCR results 
were recoded as Ct = 50.19
Definitions
Gastro-intestinal symtoms, including abdominal pain, 
diarea and vomiting, were assist at each planned visit. Anemia was 
classified using age and gender-specific hemoglobin (Hb) cutoffs: 
children 18–59 months of age, Hb <11.0 g/dL, children 5.0–11.9 
age of years <11.5 g/dL, boys 12–15 years of age Hb <12.0 g/dL, 
girls >12 years of age; Hb 12.0 g/dL; boys >15 years of age, Hb 
<13.0 g/dL.20 Severe immune suppression was defined using the 
WHO definitions according to age20: 18–59 months of age, CD4% 
<10% or CD4 count <200 cells/mm3; >59 months of age, CD4 
count <100 cells/mm3.21 Anthropometric data, based on weight, 
length and age-related Z score, were calculated based on WHO 
Multicentre Growth Reference Study Group.22,23 Primary outcome 
was BMI for age Z score (BMIZ) as this parameter was applicable 
to children of all ages while weight for age only applies to children 
<10 years and HAZ is a late marker for growth recovery (>6–12 
months). Malnutrition was defined as a BMIZ less than −2 standard 
deviation (SD).24
Statistical Analysis
Data were double entered, cleaned and analyzed using SPSS 
version 19.0. The study was primarily powered to detect prevalence 
of protozoa at baseline and their change over time. Second, univari-
ate analysis assessed risk factors for protozoal infection using χ2 
test or Fisher exact test for categorical variables and independent 
sample t test for continuous variables. All P values presented are 2 
tailed and a significance level of <0.05 was used.
Ethical Considerations
The purpose of the study was explained to the guardians 
of each patient in Chichewa, and written informed consent was 
obtained before inclusion into the study from the parents or guard-
ians and assent from the children, if applicable. The study protocol 
was approved by the Research Ethics Committee of the College of 
Medicine, University of Malawi.
RESULTS
A total of 35 children were included with a mean age of 7.9 
(SD 4.2) years. Baseline characteristics are shown in Table (Sup-
plemental Digital Content 1, http://links.lww.com/INF/C976). At 
baseline, severe immune suppression was prevalent among 30% 
(10/33). Prevalence of severe immune suppression did not differ 
significantly between the different age groups: 26% (5/19) in chil-
dren <10 years of age, versus 36% (5/14) if >10 years of age; P 
= 0.56. Fifteen percentage (5/34) of children were malnourished 
(BMIZ less than −2 SD) at baseline, which dropped to 3% (1/33) 
after 12 months on ART. Gastrointestinal complaints occurred in 
40% (14/35) of children during the first 6 months of follow-up, but 
these complaints were not associated to immunosuppression how-
ever (P = 0.411).
Stool samples were available for 35 children at baseline, 27 
(77%) children at 6 months and 26 (74%) children at 12 months of 
follow-up.
Nonopportunistic Protozoa at Baseline
Nonopportunistic protozoa were detected in 40% (14/35) of 
the children at baseline (Table 1). G. lamblia was the most com-
mon protozoa and detected in 26% (9/35) of the samples. D. fragilis 
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was prevalent in 17% (6/35) of children while E. histolytica was 
not detected. Three of 9 children (33%) with G. lamblia infection 
at baseline had gastrointestinal complaints. Gastrointestinal com-
plaints among children with G. lamblia were not more common 
than among children without G. lamblia [42% (11/26), P = 0.22]. 
At baseline, BMIZ were −0.60 (SD 1.0) for G. lamblia-positive 
children versus a mean of −0.55 (SD 1.4) for negative children, 
P = 0.92. Also D. fragilis infections at baseline were not associ-
ated with gastrointestinal complaints or a significant difference in 
BMIZ scores. Respectively 50% (3/6) of the D. fragilis-positive 
children showed gastrointestinal complaints versus 38% (11/29) 
among D. fragilis-negative children, P = 0.30. BMIZ at baseline 
was +0.56 (SD 0.9) versus +0.55 (SD 1.4) in D. fragilis-positive 
and D. fragilis-negative children, respectively, P = 0.99.
Opportunistic Protozoa at Baseline
Opportunistic protozoa were detected in 46% (16/35) of 
children at baseline. E. bieneusi was the most common opportun-
istic protozoa, present in 37% of samples (13/35). Gastrointestinal 
complaints were more common among children with E. bieneusi at 
baseline than those without infection [43% (10/13) vs. 18% (4/22), 
P = 0.001; Table 2]. Children with and without E. bieneusi had a 
similar BMIZ at baseline; BMIZ −0.6 (SD 1.0) versus BMIZ −0.6 
(SD 1.4), P = 0.92. The clinical relevance E. bieneusi infection is 
described in detail below. Cryptosporidium spp. was seen in 11% 
(4/35) of children, while Encephalitozoon spp. (ie, E. intestinalis) 
and C. belli were not detected at baseline. Cryptosporidium spp. 
infections at baseline were not associated with gastrointestinal 
complaints [42% (13/31) vs. 25% (1/4) for Cryptosporidium spp. 
positive and negative children, respectively; P = 0.42]. No differ-
ence in mean BMIZ at baseline was seen: −0.16 (SD 0.4) versus 
−0.57 (SD 1.3), P = 0.56 for Cryptosporidium spp. positive and 
negative children, respectively.
Effect of 12 Months ART on Intestinal Protozoa
The prevalence of nonopportunistic protozoa and opportun-
istic protozoa infections over time are described in Table 1. Nonop-
portunistic protozoa were present in 43% (15/35) of the children at 
baseline and 42% (11/26) after 12 months of ART. The prevalence 
of G. lamblia dropped from 26% (9/35) to 11% (3/26); however, 
new infections also occurred (Table 1). Prevalence of D. fragilis 
increased from 17% (6/35) toward 31% (8/26) after ART initiation. 
All opportunistic protozoa, including E. bieneusi, were cleared 
after 12 months of ART.
E. bieneusi
To identify children at risk for E. bieneusi and to assess 
the clinical importance of the infection, potential risk factors and 
symptoms were compared between children with and without 
E. bieneusi (Table 2). E. bieneusi was more common in children 
older than 10 years of age when compared with younger children 
[57% (8/14) vs. 24% (5/21), respectively; P = 0.05]. Children with 
E. bieneusi, when compared with children without, did not suffer 
from more severe immune suppression at baseline [38.5% (5/13) 
vs. 25.0% (5/15); P = 0.46]. However, children with and without 
E. bieneusi had a similar BMIZ at baseline; significant differences 
were seen after 12 months of ART. Children with an E. bieneusi 
infection showed a trend toward lower BMIZ when compared with 
those without; BMIZ −0.36 (SD 0.97) versus BMIZ +0.56 (SD 
1.39), P = 0.052 (Fig. 1A). BMIZ recovery after 12 months was 
+0.29 (SD 0.83) versus +1.03 (SD 1.25; P = 0.050) for E. bieneusi 
infection versus noninfected children. Children with high levels 
of E. bieneusi DNA in their stool showed a nonsignificant trend 
toward a more delayed BMI recovery (Fig. 1B). BMIZ at 12 months 
of follow-up was −0.47 (SD 1.03), −0.20 (SD 0.97) versus +0.56 
(SD 1.39) for high, low to moderate and negative baseline E. bie-
neusi DNA levels, respectively (P = 0.25).
DISCUSSION
This study presents important new PCR prevalence data 
evaluating nonopportunistic and opportunistic intestinal protozoa 
infections in HIV-infected African children receiving ART. E. bie-
neusi, an opportunistic infection, was the most prevalent intestinal 
protozoa. Despite being a rather unknown opportunistic infection 
among pediatric clinicians, E. bieneusi was not only common but 
also might be clinically relevant, as it was associated with both 
gastrointestinal complaints and possible reduced BMI recovery. 
Although all children cleared E. bieneusi by 12 months of ART and 
gastrointestinal complaints diminished, the BMI recovered poorly 
in those with an E. bieneusi infection.
Thirty-seven percentage of the ART naïve HIV-infected 
children were infected with E. bieneusi in this cohort. The 
reported prevalence of E. bieneusi in the literature shows wide 
ranges (0.8%–79%) of E. bieneusi prevalence. This may be 
explained by differences in diagnostic methods, demographics 
and study populations, including ages, presence of clinical symp-
toms, other underlying conditions and severity of the immune 
TABLE 1. Multiplex Real-time PCR Results of 
Protozoal Infections in HIV-infected Children During the 
First Year of ART
 
Baseline  
(n = 35)
6 mo  
(n = 27)
12 mo  
(n = 26)
Nonopportunistic protozoa
  Giardia lamblia
   Total positive 9 (26%) 4 (15%)* 3 (12%)†
   High DNA level 2/9 (22%) 2/4 (50%) 1/3 (33%)
   Moderate DNA level 5/9 (56%) 0/4 (0%) 1/3 (33%)
   Low DNA level 2/9 (22%) 2/4 (50%) 1/3 (33%)
  Dientamoeba fragilis
   Total positive 6 (17%) 6 (22%)‡ 8 (31%)§
   High DNA level 4/6 (67%) 2/6 (33%) 1/8 (13%)
   Moderate DNA level 2/6 (33%) 2/6 (33%) 5/8 (63%)
   Low DNA level 0/6 (0%) 2/6 (33%) 3/8 (34%)
Opportunistic protozoa
  Enterocytozoon bieneusi
   Total positive 13 (37%) 6 (22%) 0 (0%)
   High DNA level 7/13 (54%) 3/6 (50%)  
   Moderate DNA level 3/13 (23%) 2/6 (33%)  
   Low DNA level 3/13 (23%) 1/6 (17%)  
  Cryptosporidium spp.
   Total positive 4 (11%) 3 (11%)║ 0 (0%)
   High DNA level 0/4 (0%) 1/3 (33%)  
   Moderate DNA level 0/4 (0%) 1/3 (33%)  
   Low DNA level 4/4 (100%) 1/3 (33%)  
  Cystoisospora belli
   Total positive 0 (0%) 2**(7%) 0 (0%)
   High DNA level  0/2 (0%)  
   Moderate DNA level  1/2 (50%)  
   Low DNA level  1/2 (50%)  
Entamoeba histolytica and Encephalitozoon spp. (ie, Encephalitozoon intestinalis) 
were not detected. Combined E. bieneusi-Cryptosporidium infection at baseline was 
seen in 3%; 1/35 and E. bieneusi combined with G. lamblia infection at baseline was 
seen among 11%; 4/35. Detected DNA level based on cycle threshold value: Total posi-
tive: cycle threshold < 50, low DNA level: cycle threshold 35–50, moderate DNA level: 
cycle threshold 30–35 and high DNA level: cycle threshold < 30.
*No new infections.
†2 new infections.
‡6 new infections.
§7 new infections.
¶4 new infections.
║3 new infections.
**All new infections.
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suppression.25–27 Two other studies which used PCR-based assays 
in HIV-infected African children reported prevalence rates rang-
ing from 20%—in a general population of HIV-infected children 
in South Africa to 79%—in children with HIV and diarrhea in 
Uganda of E. bieneusi infection.5,27 In the current study, all chil-
dren cleared E. bieneusi and other opportunistic protozoa follow-
ing immune recovery after 12 months of ART. This is the first 
pediatric cohort study evaluating nonopportunistic and opportun-
istic intestinal protozoa infections including E. bieneusi during 
ART. However, the data collected in children are corroborating 
with data in adults showing clearance of the E. bieneusi infec-
tion after receiving several months of ART.9,10 The finding that 
children clear opportunistic protozoa are especially reassuring as 
children are considered to be more vulnerable to E. bieneusi as it 
is more common in children than adults.25
Gastrointestinal complaints are commonly reported in 
microsporidial infections such as E. bieneusi.28,29 In the current 
study, 43% of the children with a PCR-detected E. bieneusi infec-
tion described gastrointestinal complaints. The prevalence of gas-
trointestinal symptoms corroborates data in HIV-infected adults, 
where E. bieneusi infection has been associated with diarrhea and 
vomiting.28,29 More importantly this cohort demonstrated that E. 
bieneusi is associated with a delayed BMI recovery, which per-
sisted despite protozoal clearance and reduction of gastrointestinal 
complaints. Others, cross sectional studies have also reported an 
association between malnutrition, lower rates of weight gain and 
E. bieneusi in HIV infected patients.28,30,31 Malnutrition and lower 
rates of weight gain are usually attributed to ongoing diarrhea and 
impaired absorption of micronutrients because of mucosal damage 
and malabsorption caused by direct replication of protozoa in the 
TABLE 2. Factors Associated at Baseline and Over 12 Months Follow-up 
With Encephalitozoon bieneusi Infection at Baseline
 
E. bieneusi-negative 
DNA Level
E. bieneusi-positive 
DNA Level P
Odds Ratio  
(95% CI)
Sex: boys 9/22 (41%) 8/13 (62%) 0.31 0.4 (0.1–1.8)
Age, yr [mean (±SD)] 6.85 (±3.6) 9.8 (±4.5) 0.04 1.2 (1.0–1.5)
Symptoms
  Gastrointestinal symptoms*
   0–6 mo† 4/22 (18%) 10/13(43%) 0.001‡ 15.0 (2.8–80.9)
  Diarrhea
   0–6 mo† 1/22 (5%) 6/13 (46%) 0.003‡ 18.0 (1.8–176.6)
  Vomiting
   0–6 mo† 1/22 (5%) 7/13 (54%) 0.001‡ 24.5 (2.5–240.3)
Immune status
  WHO
   I 10/22 (46%) 6/13 (46%) 0.85 -
   II 5/22 (23%) 2/13 (15%)   
   III 7/22 (32%) 5/13(39%)   
   IV 0 0/39 (0%)   
  Severe immune suppression§
   Baseline 5/20 (25%) 5/13 (39%) 0.41 1.9 (0.4–8.5)
*Gastrointestinal symptoms include abdominal pain or diarrhea or vomiting.
†Complaints during 0–6 mo follow-up.
‡P significant <0.05. Toilet use and water availability did not differ significant between children with and without 
E. bieneusi infection (data not shown).
§Severe immune suppression: age <59 mo: CD4% <10% or a CD4 count <200 cells/mm320; age >59 mo: CD4 count 
<100 cells/mm3.21
CI indicates confidence interval; WHO, world Health Organization.
A
B
FIGURE 1. BMIZ of children with and 
without detectable Enterocytozoon Bieneusi 
DNA levels during 12 months of ART. BMIZ 
calculated based on WHO Multicentre Growth 
Reference Study Group.20,21. A: After 12 
months follow-up, the BMIZ remained lower 
in children with E. bieneusi in comparison 
to those without E. bieneusi infection; BMIZ 
−0.36 versus BMIZ +0.56; P = 0.05. B: After 12 
months follow-up, the BMIZ remained lower 
in children with E. bieneusi high DNA level in 
comparison to those with moderate to low and 
a negative E. bieneusi DNA level: BMIZ −0.47, 
−0.20 versus +0.56 for high, low to moderate 
and negative E. bieneusi DNA levels at baseline; 
P = 0.25. Detected DNA level based on Ct 
value: Low to moderate DNA level: Ct 30–50 
and high DNA level: Ct < 30. 
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epithelium of small intestine.29 In this study, the gastrointestinal 
complaints resolved within 6 months and immune status improved 
during 12 months of ART, while a poor nutritional state, signified 
by delayed BMI recovery, persisted. Second, there was no associa-
tion between potential confounders such as immune suppression 
at baseline (Table 2), neither tuberculosis infection at enrolment 
nor ART failure at 12 months and BMI recovery in this population 
(data not shown). Further studies are needed to assess if the effect 
on BMI is secondary to a direct effect of E. bieneusi on the mucosa 
or if more factors are involved in the delayed BMI recovery.
Like other studies, a large part of patients with an E. bie-
neusi infection detected by PCR are asymptomatic.5,25 However, 
other studies have not assessed if the lower protozoal load may 
explain why some do not have symptoms.5,25 Low detectable DNA 
levels may, for instance, reflect spore shedding rather than actual 
infection.6,31–33 E. bieneusi spores are detected in stool specimens by 
microscopy for 9–33 days, while stool specimens evaluated by PCR 
are positive for 3–40 days longer.25 PCR results should therefore 
be interpreted with some care, especially if low DNA levels are 
detected. Despite this, we did identify a trend toward a poorer BMI 
recovery among children with high E. bieneusi DNA levels in this 
relatively small study.
None of the children received treatment after their PCR 
results in this study. Given our finding of a significant association 
between E. bieneusi and a poor BMI recovery and clinical symp-
toms, the differences found were small and both may have multiple 
causes. Therefore, the effect of therapy for E. bieneusi on these out-
comes should be tested in a placebo-controlled trial. Effective treat-
ment for E. bieneusi is complex, however. Albendazol has shown 
conflicting results in the treatment of different E. bieneusi subtype 
infections.34,35 Fumagillin, a newer agent, was shown to be effective 
in adults and was approved in 2005, but severe adverse effects limit 
its use and availability.35,36 If these restrictions also apply to children 
is unclear, as paediatric data are very limited. However data avail-
able show good effectiveness and no side effects.36 TPN 470, the 
fumagillin analogue, may be a potentially safer alternative though 
it again lacks pediatric testing.2,34,35 Given the serious reduced BMI 
recovery in these HIV-infected children, phase 2 and 3 trials should 
be considered.
Besides E. bieneusi, G. lamblia was a common nonoppor-
tunistic pathogen. Prevalence of G. lamblia worldwide can differ 
enormously due to diagnostic test, population, demographics, sea-
son and ages.37,38 Our reported PCR-detected prevalence of 26% is 
similar to a previously reported prevalence of 30% among severely 
malnourished children in Blantyre, Malawi.39 Immune status recov-
ery has a questionable effect on infection while the prevalence of G. 
lamblia dropped from 26% toward 11% during 12 months of ART, 
new infections also occurred. G. lamblia infection can present 
with gastrointestinal complaints, but carriers may also be asymp-
tomatic.37,40 In this study, gastrointestinal complaints and malnutri-
tion could not be linked to G. lamblia infection. As we detected 
mainly moderate and low DNA loads (78%), we may have identi-
fied a large proportion of asymptomatic carriers. As G. lamblia is 
not an opportunistic infection, it is unlikely that prevalence will be 
reduced by restored immunity due to ART.
Cryptosporidium spp. occurred in this study but infections 
resolved after immune recovery during ART and DNA levels were 
only high in 2 children. Earlier PCR-based studies in Malawi (Blan-
tyre) among preschool children with diarrhea and an unknown 
HIV status showed a comparable prevalence of Cryptosporidium 
spp. of 5%–9%.41 Cryptosporidiosis is commonly associated with 
symptoms of diarrhea; however, in this study, gastrointestinal com-
plaints were not associated with infection.42 This effect may be 
explained by the relatively low to moderate infection prevalence 
of all Cryptosporidium spp. infection at baseline as compared with 
other pathogens. Considering the low prevalence and the lack of an 
effective treatment in children, routine testing will likely not ben-
efit children in an outpatient setting.43 Combined infections were 
not common among the presenting cohort. Clinical symptoms are 
therefore not related and influenced by coinfections.
This study had several limitations. First, this study used 
local guidelines to start ART in Malawi in 2010, which meant that 
the studied cohort was severely immune compromised in com-
parison to current cohorts of children starting ART. Current WHO 
guidelines suggest to start ART early in the course of HIV disease.21 
Current HIV-infected populations may therefore have lower proto-
zoal prevalence rates. Given the high prevalence in our study and 
the fact that HIV diagnosis still is often delayed in African set-
tings, we believe our findings are still important. Second, the num-
ber of children recruited is small and follow-up was stopped at 12 
months; therefore, associations may have been missed or suggested 
that required a larger sample size or prolonged follow-up. Still this 
study is the first pediatric cohort from Africa using PCR techniques 
with 12 months of follow-up during ART. Third, the use of PCR 
may have overestimated the prevalence of pathogens over time as 
PCR also detects spores, which are not active pathogens.6,31–33 How-
ever, we assessed the effect of DNA load and were able to show 
a trend toward a more delayed BMI recovery in children with a 
higher load. To confirm this effect, more research is needed to 
investigate the duration of diminished growth after 24 months and 
the eventual effect of (repeated presumptive) treatment on growth 
over time. Finally, we have not performed of E. bieneusi subtype 
analysis, this information could be of use as clinical presentation 
is influenced by genotype and therefore may vary in different geo-
graphic regions.44,45
This prospective cohort reports on the prevalence of intes-
tinal protozoa in HIV-infected children in Malawi, during the first 
year of first-line ART using multiplex real-time PCR techniques. 
E. bieneusi is a very common pathogen at start of ART and clini-
cally important as it was associated with gastrointestinal complains 
and may be associated with prolonged reduced growth, a predictor 
of poor prognosis. Future studies should focus on trials to assess 
treatment options for E. bieneusi to improve symptoms and poor 
nutrition status.
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